

## **CORRIGENDA**

**WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease**

**ISBN 978-92-4-002267-6 (electronic version)**

**ISBN 978-92-4-002268-3 (print version)**

### **Page vi, lines 13–15**

*Delete:* PICO question 10 (accuracy of screening approaches in children and adolescents): Anna Mandalakas, Tara Ness and Bryan Vonasek (Baylor College of Medicine, USA); and Karen Steingart (Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine).

*Insert:* PICO question 10 (accuracy of screening approaches in children and adolescents): Anna Mandalakas, Tara Ness and Bryan Vonasek (Baylor College of Medicine, USA); Karen Steingart (Cochrane Infectious Diseases Group, Liverpool School of Tropical Medicine); and Yemisi Takwoingi (University of Birmingham, United Kingdom) .

### **Page vii, lines 3–9**

*Delete:* The following persons participated as observers at the GDG meetings: Sevim Ahmedov and Charlotte Colvin (United States Agency for International Development, USA), Draurio Barreira Cravo Neto (Unitaid, Switzerland), Olivia Bierman (Karolinska Institute, Sweden), Michael Campbell (Clinton Health Access Initiative, USA), Pierre-Marie David (Université de Montréal, Canada), Christopher Gilpin (International Organization for Migration, Switzerland), Brian Kaiser (Global Drug Facility, Switzerland) and Mohammed Yassin (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland).

*Insert:* The following persons participated as observers at the GDG meetings: Sevim Ahmedov and Charlotte Colvin (United States Agency for International Development, USA), Draurio Barreira Cravo Neto (Unitaid, Switzerland), Olivia Bierman (Karolinska Institute, Sweden), Michael Campbell (Clinton Health Access Initiative, USA), Jacob Creswell (Stop TB Partnership, Switzerland), Pierre-Marie David (Université de Montréal, Canada), Christopher Gilpin (International Organization for Migration, Switzerland), Brian Kaiser (Global Drug

Facility, Switzerland) and Mohammed Yassin (Global Fund to Fight AIDS, Tuberculosis and Malaria, Switzerland).

**Page 5, lines 23–25**

*Delete:* For the purpose of this guideline, systematic screening for TB disease is defined as the systematic identification of people at risk for TB disease, in a predetermined target group, by assessing using tests, examinations or other procedures that can be applied rapidly.

*Insert:* For the purpose of this guideline, systematic screening for TB disease is defined as the systematic identification of people at risk for TB disease, in a predetermined target group, by assessing symptoms and using tests, examinations or other procedures that can be applied rapidly.

**Page 31, lines 3–6**

*Delete:* When performed before the W4SS among people living with HIV, CRP with a cut-off of  $> 5$  mg/L as an initial screening test was found to be as sensitive (0.78; 95% CI: 0.70–0.85) as the W4SS but to have significantly higher specificity (0.73; 95% CI: 0.66–0.79) in this subpopulation.

*Insert:* When performed sequentially after a positive W4SS among people living with HIV not on ART, CRP with a cut-off of  $> 5$  mg/L was found to be as sensitive (0.84; 95% CI: 0.73–0.90) as the W4SS alone but to have significantly higher specificity (0.64; 95% CI: 0.55–0.72).

**Web Annex C. GRADE Evidence to Decision Tables**

Replaced old version with a new layed-out version. No changes to the content were made.

These corrections have been incorporated into the electronic file.